Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M

Journey Medical Corp

Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.
Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.
Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.
SG&A down $0.5M to $10.1M due to lower Emrosi launch costs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Journey Medical Corp reported the three months ended March 31, 2026 results: revenue $16.0 million, net income $(2.2) million, or $(0.08) per share basic and diluted, EPS $(0.08) per share basic and diluted.

Period: the three months ended March 31, 2026
Revenue: $16.0 million
Net income: $(2.2) million, or $(0.08) per share basic and diluted
EPS: $(0.08) per share basic and diluted
Result: reported results

Exact text from the filing

Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold

View on SEC.gov

Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-060232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.